Not checked for notices yet.

XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor

Lijia Pan, Cheng Cheng, Peiwen Duan and 3 more

Journal of Experimental & Clinical Cancer Research · 2021

doi:10.1186/s13046-021-02044-z

Cited by papers we hold 1

Small molecule inhibitors targeting the cancers · 2022
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.